0,1,2,3,4,5,6
"Table 6.3.3:  Selected studies of post-prostatectomy salvage radiotherapy, stratified by pre-salvage",,,,,,
Study,n,"Median FU 
(mo)","pre-SRT 
PSA (ng/mL) 
median","RT dose  
ADT","bNED/PFS 
(year)",5-yr. results
"Bartkowiak, 
et al. 2018 
[1039]",464,71,0.31,66.6 Gy,54% (5.9),"73% vs. 56%; PSA 
< 0.2 vs. > 0.2 ng/mL  
p < 0.0001"
"Soto, et al. 
2012 [1040]",441,36,< 1 (58%),"68 Gy 
24% ADT","63/55% (3) 
ADT/no ADT","44/40% ADT/no ADT  
p < 0.16"
"Stish, et al. 
2016 [1031]","1,106",107,0.6,"68 Gy 
16% ADT","50% (5) 
36% (10)","44% vs. 58%; PSA 
< 0.5 vs. > 0.5 ng/mL  
p < 0.001"
"Tendulkar,  
et al. 2016 
[1041]","2,460",60,0.5,"66 Gy 
16% ADT",56% (5),"Pre-SRT PSA 
71% 0.01–0.2 ng/mL
63% 0.21–0.5 ng/mL
54% 0.51–1.0 ng/mL
43% 1.01–2.0 ng/mL
37% > 2.0 ng/mL  
p < 0.001"
"Jackson, 
et al. 2014 
[1042]",448,64,68.4 Gy no ADT,"5 yr. DM 
post-SRT PSA < 0.1 ng/mL 5% 
post-SRT PSA > 0.1 ng/mL 29% 
p < 0.0001 
5 yr. DSM 
post-SRT PSA < 0.1 ng/mL 2% 
post-SRT PSA > 0.1 ng/mL 7% 
p < 0.0001 
OS 
post-SRT PSA < 0.1 ng/mL 97% 
post-SRT PSA > 0.1 ng/mL 90% 
p < 0.0001",,
"Stish, 
et al. 2016 
[1031]","1,106",107,"68 (64.8-70.2) Gy 
39% 2D treatment 
planning 
incl. 16% ADT","5 and 8.9 yr. DM 
SRT: PSA < 0.5 ng/mL 7% and 12% 
SRT: PSA > 0.5 ng/mL 14% and 23% 
p < 0.001 
5 and 8.9 yr. DSM 
SRT: PSA < 0.5 ng/mL < 1% and 6% 
SRT: PSA > 0.5 ng/mL 5% and 10% 
p = 0.02 5 and 8.9 yr. OS 
SRT: PSA < 0.5 ng/mL 94% and 86% 
SRT: PSA > 0.5 ng/mL 91% and 78% 
p = 0.14",,
"Tendulkar, 
et al. 2016 
[1041]","2,460",60,"66 (64.8-68.4) Gy 
incl. 16% ADT","10-yr. DM (19% all patients)
Pre-SRT PSA
9% 0.01–0.2 ng/mL
15% 0.21–0.5 ng/mL
19% 0.51–1.0 ng/mL
20% 1.01–2.0 ng/mL
37% > 2.0 ng/mL
p < 0.001",,
